Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry refers to a long non-coding RNA (lncRNA) identified as a "novel transcript, antisense to ANKRD54 and SYN3," annotated in genomic databases such as Ensembl with the gene ID ENSG00000299801[1]. As a natural antisense transcript (NAT), it is transcribed from the opposite DNA strand relative to the protein-coding ANKRD54 and SYN3 genes and may partially overlap them at the nucleotide level. NATs like this can exert diverse regulatory effects on their sense gene partners, including transcriptional interference (colliding RNA polymerases result in reduced gene expression), RNA masking (impairing splicing or translation), and involvement in epigenetic regulation via chromatin modifications[2][4]. While the broad class of NATs has been implicated in gene expression regulation and some disease contexts, there is no direct evidence indicating therapeutic relevance, disease implication, or druggability for this specific transcript as of the current data[3]. Its functional annotation remains limited, and it is not currently considered a therapeutic target in pharmacology or medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to ANKRD54 and SYN3 (ENSG00000299801).